Protara Therapeutics, Inc. (NASDAQ:TARA) insider upped their holding by 222% earlier this year
From what we can see, insiders were net buyers in Protara Therapeutics, Inc.'s (NASDAQ:TARA ) during the past 12 months. That is, insiders acquired the stock in greater numbers than they sold it.
Although we don't think shareholders should simply follow insider transactions, we do think it is perfectly logical to keep tabs on what insiders are doing.
View our latest analysis for Protara Therapeutics
The Last 12 Months Of Insider Transactions At Protara Therapeutics
In the last twelve months, the biggest single purchase by an insider was when insider Martin Olivo bought US$100k worth of shares at a price of US$10.13 per share. That means that an insider was happy to buy shares at above the current price of US$4.25. It's very possible they regret the purchase, but it's more likely they are bullish about the company. We always take careful note of the price insiders pay when purchasing shares. It is encouraging to see an insider paid above the current price for shares, as it suggests they saw value, even at higher levels. The only individual insider to buy over the last year was Martin Olivo.
You can see the insider transactions (by companies and individuals) over the last year depicted in the chart below. By clicking on the graph below, you can see the precise details of each insider transaction!
Protara Therapeutics is not the only stock that insiders are buying. For those who like to find winning investments this free list of growing companies with recent insider purchasing, could be just the ticket.
Insider Ownership
I like to look at how many shares insiders own in a company, to help inform my view of how aligned they are with insiders. We usually like to see fairly high levels of insider ownership. Our data indicates that Protara Therapeutics insiders own about US$7.3m worth of shares (which is 15% of the company). We do generally prefer see higher levels of insider ownership.
What Might The Insider Transactions At Protara Therapeutics Tell Us?
It doesn't really mean much that no insider has traded Protara Therapeutics shares in the last quarter. But insiders have shown more of an appetite for the stock, over the last year. While we have no worries about the insider transactions, we'd be more comfortable if they owned more Protara Therapeutics stock. So these insider transactions can help us build a thesis about the stock, but it's also worthwhile knowing the risks facing this company. Be aware that Protara Therapeutics is showing 4 warning signs in our investment analysis, and 1 of those is concerning...
But note: Protara Therapeutics may not be the best stock to buy. So take a peek at this free list of interesting companies with high ROE and low debt.
For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions, but not derivative transactions.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
